img

Global Blood Tumor Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Blood Tumor Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Blood Tumor, also known as hematological disease, is a type of cancer impacting bone marrow, blood, and lymph nodes. Different sorts of mature blood cells include white blood cells for immune protection, platelets for wound clotting, and red blood cells to carry oxygen. In the bone marrow, it originates from progenitor cells and hematopoietic stem. Hematologic malignancies initiate in these cells and are subcategorized as per the type of blood cell that is affected such as myeloid or myelogenous or and lymphocytic lymphoblastic. A malignancy in the lymphoid lineage involves B lymphocytes and T lymphocytes. Malignancy in the myeloid lineage involves precursor cells to white blood cells platelets and red blood cells.
Due to the COVID-19 pandemic, the global Blood Tumor Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Chemotherapy accounting for % of the Blood Tumor Treatment global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Leukemia segment is altered to an % CAGR throughout this forecast period.
The global key companies of Blood Tumor Treatment include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer and AstraZeneca, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Blood Tumor Treatment market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Blood Tumor Treatment landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Blood Tumor Treatment market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Blood Tumor Treatment market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Blood Tumor Treatment market. Readers of the report can become informed about current and future trends of the global Blood Tumor Treatment market and how they will impact market growth during the forecast period.



By Company


Bristol-Myers Squibb
Johnson & Johnson
AbbVie
Novartis
Roche
Amgen
Takeda
Pfizer
AstraZeneca
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Other

Segment by Application


Leukemia
Lymphoma
Multiple Myeloma
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Blood Tumor Treatment in global and regional level.
Chapter 3Detailed analysis of Blood Tumor Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Tumor Treatment revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Tumor Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Blood Tumor Treatment Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Multiple Myeloma
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Blood Tumor Treatment Market Size (2018-2034)
2.2 Blood Tumor Treatment Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Blood Tumor Treatment Market Size by Region (2018-2024)
2.4 Global Blood Tumor Treatment Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Blood Tumor Treatment Countries Ranking by Market Size
3 Blood Tumor Treatment Competitive by Company
3.1 Global Blood Tumor Treatment Revenue by Players
3.1.1 Global Blood Tumor Treatment Revenue by Players (2018-2024)
3.1.2 Global Blood Tumor Treatment Market Share by Players (2018-2024)
3.2 Global Blood Tumor Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Blood Tumor Treatment Revenue
3.4 Global Blood Tumor Treatment Market Concentration Ratio
3.4.1 Global Blood Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Tumor Treatment Revenue in 2022
3.5 Global Key Players of Blood Tumor Treatment Head office and Area Served
3.6 Global Key Players of Blood Tumor Treatment, Product and Application
3.7 Global Key Players of Blood Tumor Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Blood Tumor Treatment Breakdown Data by Type
4.1 Global Blood Tumor Treatment Historic Revenue by Type (2018-2024)
4.2 Global Blood Tumor Treatment Forecasted Revenue by Type (2024-2034)
5 Global Blood Tumor Treatment Breakdown Data by Application
5.1 Global Blood Tumor Treatment Historic Market Size by Application (2018-2024)
5.2 Global Blood Tumor Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Blood Tumor Treatment Revenue by Company (2021-2024)
6.2 North America Blood Tumor Treatment Revenue by Type (2018-2034)
6.3 North America Blood Tumor Treatment Revenue by Application (2018-2034)
6.4 North America Blood Tumor Treatment Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Blood Tumor Treatment Revenue by Company (2021-2024)
7.2 Europe Blood Tumor Treatment Revenue by Type (2018-2034)
7.3 Europe Blood Tumor Treatment Revenue by Application (2018-2034)
7.4 Europe Blood Tumor Treatment Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Blood Tumor Treatment Revenue by Company (2021-2024)
8.2 Asia Pacific Blood Tumor Treatment Revenue by Type (2018-2034)
8.3 Asia Pacific Blood Tumor Treatment Revenue by Application (2018-2034)
8.4 Asia Pacific Blood Tumor Treatment Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Blood Tumor Treatment Revenue by Company (2021-2024)
9.2 Latin America Blood Tumor Treatment Revenue by Type (2018-2034)
9.3 Latin America Blood Tumor Treatment Revenue by Application (2018-2034)
9.4 Latin America Blood Tumor Treatment Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Blood Tumor Treatment Revenue by Company (2021-2024)
10.2 Middle East and Africa Blood Tumor Treatment Revenue by Type (2018-2034)
10.3 Middle East and Africa Blood Tumor Treatment Revenue by Application (2018-2034)
10.4 Middle East and Africa Blood Tumor Treatment Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Blood Tumor Treatment Products and Services
11.1.4 Bristol-Myers Squibb Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.1.5 Bristol-Myers Squibb Blood Tumor Treatment SWOT Analysis
11.1.6 Bristol-Myers Squibb Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Blood Tumor Treatment Products and Services
11.2.4 Johnson & Johnson Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.2.5 Johnson & Johnson Blood Tumor Treatment SWOT Analysis
11.2.6 Johnson & Johnson Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Blood Tumor Treatment Products and Services
11.3.4 AbbVie Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.3.5 AbbVie Blood Tumor Treatment SWOT Analysis
11.3.6 AbbVie Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Blood Tumor Treatment Products and Services
11.4.4 Novartis Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.4.5 Novartis Blood Tumor Treatment SWOT Analysis
11.4.6 Novartis Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Blood Tumor Treatment Products and Services
11.5.4 Roche Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.5.5 Roche Blood Tumor Treatment SWOT Analysis
11.5.6 Roche Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Blood Tumor Treatment Products and Services
11.6.4 Amgen Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.6.5 Amgen Blood Tumor Treatment SWOT Analysis
11.6.6 Amgen Recent Development
11.7 Takeda
11.7.1 Takeda Company Details
11.7.2 Takeda Business Overview
11.7.3 Takeda Blood Tumor Treatment Products and Services
11.7.4 Takeda Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.7.5 Takeda Blood Tumor Treatment SWOT Analysis
11.7.6 Takeda Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Blood Tumor Treatment Products and Services
11.8.4 Pfizer Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.8.5 Pfizer Blood Tumor Treatment SWOT Analysis
11.8.6 Pfizer Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Blood Tumor Treatment Products and Services
11.9.4 AstraZeneca Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.9.5 AstraZeneca Blood Tumor Treatment SWOT Analysis
11.9.6 AstraZeneca Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Blood Tumor Treatment Products and Services
11.10.4 Gilead Sciences Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024)
11.10.5 Gilead Sciences Blood Tumor Treatment SWOT Analysis
11.10.6 Gilead Sciences Recent Development
12 Blood Tumor Treatment Market Dynamics
12.1 Blood Tumor Treatment Industry Trends
12.2 Blood Tumor Treatment Market Drivers
12.3 Blood Tumor Treatment Market Challenges
12.4 Blood Tumor Treatment Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Blood Tumor Treatment Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Immunotherapy
Table 5. Key Players of Other
Table 6. Global Blood Tumor Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 7. Global Blood Tumor Treatment Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 8. Global Blood Tumor Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Blood Tumor Treatment Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 10. Global Blood Tumor Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 11. Global Blood Tumor Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 12. Global Blood Tumor Treatment Market Share by Players (2018-2024)
Table 13. Global Top Blood Tumor Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Tumor Treatment as of 2022)
Table 14. Ranking of Global Top Blood Tumor Treatment Companies by Revenue (US$ Million) in 2022
Table 15. Global 5 Largest Players Market Share by Blood Tumor Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 16. Global Key Players of Blood Tumor Treatment, Headquarters and Area Served
Table 17. Global Key Players of Blood Tumor Treatment, Product and Application
Table 18. Global Key Players of Blood Tumor Treatment, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Blood Tumor Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 21. Global Blood Tumor Treatment Revenue Market Share by Type (2018-2024)
Table 22. Global Blood Tumor Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 23. Global Blood Tumor Treatment Revenue Market Share by Type (2024-2034)
Table 24. Global Blood Tumor Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 25. Global Blood Tumor Treatment Revenue Market Share by Application (2018-2024)
Table 26. Global Blood Tumor Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 27. Global Blood Tumor Treatment Revenue Market Share by Application (2024-2034)
Table 28. North America Blood Tumor Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 29. North America Blood Tumor Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 30. North America Blood Tumor Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 31. North America Blood Tumor Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 32. North America Blood Tumor Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 33. North America Blood Tumor Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 34. North America Blood Tumor Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 35. North America Blood Tumor Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 36. Europe Blood Tumor Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 37. Europe Blood Tumor Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 38. Europe Blood Tumor Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 39. Europe Blood Tumor Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 40. Europe Blood Tumor Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 41. Europe Blood Tumor Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 42. Europe Blood Tumor Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 43. Europe Blood Tumor Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 44. Asia Pacific Blood Tumor Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 45. Asia Pacific Blood Tumor Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 46. Asia Pacific Blood Tumor Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 47. Asia Pacific Blood Tumor Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 48. Asia Pacific Blood Tumor Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 49. Asia-Pacific Blood Tumor Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 50. Asia Pacific Blood Tumor Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 51. Asia Pacific Blood Tumor Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 52. Latin America Blood Tumor Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 53. Latin America Blood Tumor Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 54. Latin America Blood Tumor Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 55. Latin America Blood Tumor Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 56. Latin America Blood Tumor Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 57. Latin America Blood Tumor Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 58. Latin America Blood Tumor Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 59. Latin America Blood Tumor Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 60. Middle East and Africa Blood Tumor Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 61. Middle East and Africa Blood Tumor Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Blood Tumor Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Blood Tumor Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Blood Tumor Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Blood Tumor Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 66. Middle East and Africa Blood Tumor Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Blood Tumor Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 68. Bristol-Myers Squibb Company Details
Table 69. Bristol-Myers Squibb Business Overview
Table 70. Bristol-Myers Squibb Blood Tumor Treatment Product and Services
Table 71. Bristol-Myers Squibb Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 72. Bristol-Myers Squibb Blood Tumor Treatment SWOT Analysis
Table 73. Bristol-Myers Squibb Recent Development
Table 74. Johnson & Johnson Company Details
Table 75. Johnson & Johnson Business Overview
Table 76. Johnson & Johnson Blood Tumor Treatment Product and Services
Table 77. Johnson & Johnson Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 78. Johnson & Johnson Blood Tumor Treatment SWOT Analysis
Table 79. Johnson & Johnson Recent Development
Table 80. AbbVie Company Details
Table 81. AbbVie Business Overview
Table 82. AbbVie Blood Tumor Treatment Product and Services
Table 83. AbbVie Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 84. AbbVie Blood Tumor Treatment SWOT Analysis
Table 85. AbbVie Recent Development
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Blood Tumor Treatment Product and Services
Table 89. Novartis Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 90. Novartis Blood Tumor Treatment SWOT Analysis
Table 91. Novartis Recent Development
Table 92. Roche Company Details
Table 93. Roche Business Overview
Table 94. Roche Blood Tumor Treatment Product and Services
Table 95. Roche Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 96. Roche Blood Tumor Treatment SWOT Analysis
Table 97. Roche Recent Development
Table 98. Amgen Company Details
Table 99. Amgen Business Overview
Table 100. Amgen Blood Tumor Treatment Product and Services
Table 101. Amgen Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 102. Amgen Blood Tumor Treatment SWOT Analysis
Table 103. Amgen Recent Development
Table 104. Takeda Company Details
Table 105. Takeda Business Overview
Table 106. Takeda Blood Tumor Treatment Product and Services
Table 107. Takeda Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 108. Takeda Blood Tumor Treatment SWOT Analysis
Table 109. Takeda Recent Development
Table 110. Pfizer Company Details
Table 111. Pfizer Business Overview
Table 112. Pfizer Blood Tumor Treatment Product and Services
Table 113. Pfizer Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 114. Pfizer Blood Tumor Treatment SWOT Analysis
Table 115. Pfizer Recent Development
Table 116. AstraZeneca Company Details
Table 117. AstraZeneca Business Overview
Table 118. AstraZeneca Blood Tumor Treatment Product and Services
Table 119. AstraZeneca Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 120. AstraZeneca Blood Tumor Treatment SWOT Analysis
Table 121. AstraZeneca Recent Development
Table 122. Gilead Sciences Company Details
Table 123. Gilead Sciences Business Overview
Table 124. Gilead Sciences Blood Tumor Treatment Product and Services
Table 125. Gilead Sciences Blood Tumor Treatment Revenue in Blood Tumor Treatment Business (2018-2024) & (US$ Million)
Table 126. Gilead Sciences Blood Tumor Treatment SWOT Analysis
Table 127. Gilead Sciences Recent Development
Table 128. Blood Tumor Treatment Market Trends
Table 129. Blood Tumor Treatment Market Drivers
Table 130. Blood Tumor Treatment Market Challenges
Table 131. Blood Tumor Treatment Market Restraints
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Blood Tumor Treatment Product Picture
Figure 2. Global Blood Tumor Treatment Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Blood Tumor Treatment Market Share by Type: 2022 VS 2034
Figure 4. Chemotherapy Features
Figure 5. Targeted Therapy Features
Figure 6. Immunotherapy Features
Figure 7. Other Features
Figure 8. Global Blood Tumor Treatment Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 9. Global Blood Tumor Treatment Market Share by Application: 2022 VS 2034
Figure 10. Leukemia
Figure 11. Lymphoma
Figure 12. Multiple Myeloma
Figure 13. Others
Figure 14. Blood Tumor Treatment Report Years Considered
Figure 15. Global Blood Tumor Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Blood Tumor Treatment Market Size 2018-2034 (US$ Million)
Figure 17. Global Blood Tumor Treatment Market Size Market Share by Region: 2022 VS 2034
Figure 18. Global Blood Tumor Treatment Revenue Market Share by Region in 2018 VS 2022
Figure 19. Global Blood Tumor Treatment Revenue Market Share Forecast by Region (2024-2034)
Figure 20. Global Top 10 Blood Tumor Treatment Countries Ranking by Market Size (US$ Million) in 2022
Figure 21. Global Blood Tumor Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 22. Global Blood Tumor Treatment Market Share by Players in 2022
Figure 23. Global Top Blood Tumor Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Tumor Treatment as of 2022)
Figure 24. The Top 10 and 5 Players Market Share by Blood Tumor Treatment Revenue in 2022
Figure 25. North America Blood Tumor Treatment Revenue Market Share by Company in 2022
Figure 26. North America Blood Tumor Treatment Revenue Market Share by Type (2018-2034)
Figure 27. North America Blood Tumor Treatment Revenue Market Share by Application (2018-2034)
Figure 28. North America Blood Tumor Treatment Revenue Share by Country (2018-2034)
Figure 29. United States Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 30. Canada Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 31. Europe Blood Tumor Treatment Revenue Market Share by Company in 2022
Figure 32. Europe Blood Tumor Treatment Revenue Market Share by Type (2018-2034)
Figure 33. Europe Blood Tumor Treatment Revenue Market Share by Application (2018-2034)
Figure 34. Europe Blood Tumor Treatment Revenue Share by Country (2018-2034)
Figure 35. Germany Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 36. France Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 37. U.K. Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 38. Italy Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 39. Russia Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 40. Asia Pacific Blood Tumor Treatment Revenue Market Share by Company in 2022
Figure 41. Asia Pacific Blood Tumor Treatment Revenue Market Share by Type (2018-2034)
Figure 42. Asia Pacific Blood Tumor Treatment Revenue Market Share by Application (2018-2034)
Figure 43. Asia Pacific Blood Tumor Treatment Revenue Share by Region (2018-2034)
Figure 44. China Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 45. Japan Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 46. South Korea Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 47. India Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 48. Australia Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 49. China Taiwan Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 50. Indonesia Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 51. Thailand Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 52. Malaysia Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 53. Latin America Blood Tumor Treatment Revenue Market Share by Company in 2022
Figure 54. Latin America Blood Tumor Treatment Revenue Market Share by Type (2018-2034)
Figure 55. Latin America Blood Tumor Treatment Revenue Market Share by Application (2018-2034)
Figure 56. Latin America Blood Tumor Treatment Revenue Share by Country (2018-2034)
Figure 57. Mexico Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 58. Brazil Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 59. Argentina Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 60. Middle East and Africa Blood Tumor Treatment Revenue Market Share by Company in 2022
Figure 61. Middle East and Africa Blood Tumor Treatment Revenue Market Share by Type (2018-2034)
Figure 62. Middle East and Africa Blood Tumor Treatment Revenue Market Share by Application (2018-2034)
Figure 63. Middle East and Africa Blood Tumor Treatment Revenue Share by Country (2018-2034)
Figure 64. Turkey Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 65. Saudi Arabia Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 66. UAE Blood Tumor Treatment Revenue (2018-2034) & (US$ Million)
Figure 67. Bristol-Myers Squibb Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 68. Johnson & Johnson Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 69. AbbVie Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 70. Novartis Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 71. Roche Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 72. Amgen Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 73. Takeda Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 74. Pfizer Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 75. AstraZeneca Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 76. Gilead Sciences Revenue Growth Rate in Blood Tumor Treatment Business (2018-2024)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed